Pacific Financial Statements From 2010 to 2025

PACB Stock  USD 1.24  0.02  1.64%   
Pacific Biosciences financial statements provide useful quarterly and yearly information to potential Pacific Biosciences of investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pacific Biosciences financial statements helps investors assess Pacific Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pacific Biosciences' valuation are summarized below:
Gross Profit
47.7 M
Profit Margin
(2.00)
Market Capitalization
359.1 M
Enterprise Value Revenue
4.1656
Revenue
154 M
We have found one hundred twenty available trending fundamental ratios for Pacific Biosciences, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Pacific Biosciences recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of March 18, 2025, Market Cap is expected to decline to about 1.5 B. In addition to that, Enterprise Value is expected to decline to about 1.8 B

Pacific Biosciences Total Revenue

78.97 Million

Check Pacific Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacific Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 32 M, Interest Expense of 14.1 M or Total Revenue of 79 M, as well as many indicators such as Price To Sales Ratio of 3.1, Ptb Ratio of 4.3 or Capex To Depreciation of 0.36. Pacific financial statements analysis is a perfect complement when working with Pacific Biosciences Valuation or Volatility modules.
  
Check out the analysis of Pacific Biosciences Correlation against competitors.

Pacific Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding302.8 M288.4 M142.3 M
Slightly volatile
Total Assets2.1 BB719 M
Slightly volatile
Short and Long Term Debt Total1.1 B1.1 B330.6 M
Slightly volatile
Total Current Liabilities114.7 M109.3 M45.6 M
Slightly volatile
Other Liabilities2.8 MM20.8 M
Pretty Stable
Property Plant And Equipment Net83.3 M79.4 M41.2 M
Slightly volatile
Current Deferred Revenue13.1 M18.8 M12.9 M
Slightly volatile
Accounts Payable18.2 M17.3 M8.2 M
Slightly volatile
Cash137.4 M206.9 M131.6 M
Slightly volatile
Non Current Assets Total1.2 B1.2 B343.6 M
Slightly volatile
Non Currrent Assets Other3.7 M4.3 M3.8 M
Pretty Stable
Other Assets1.091.155.6 M
Pretty Stable
Cash And Short Term Investments762.4 M726.1 M326.4 M
Slightly volatile
Short Term Investments545.2 M519.2 M211.8 M
Slightly volatile
Liabilities And Stockholders Equity2.1 BB719 M
Slightly volatile
Non Current Liabilities Total1.1 B1.1 B374.1 M
Slightly volatile
Other Current Assets20.9 M19.9 M6.2 M
Slightly volatile
Other Stockholder Equity3.1 B2.9 B1.3 B
Slightly volatile
Total Liabilities1.3 B1.2 B419.7 M
Slightly volatile
Property Plant And Equipment Gross173.7 M165.4 M56.9 M
Slightly volatile
Total Current Assets896 M853.4 M375.4 M
Slightly volatile
Short Term Debt8.2 M11.6 M8.2 M
Slightly volatile
Property Plant Equipment98.2 M93.5 M39.9 M
Slightly volatile
Long Term Debt1.1 BB362.2 M
Slightly volatile
Net Receivables44.2 M42.1 M15.7 M
Slightly volatile
Common Stock Total Equity189 K198.9 K40.5 M
Slightly volatile
Inventory68.4 M65.2 M25.9 M
Slightly volatile
Common Stock229.1 K241.2 K83.3 M
Slightly volatile
Long Term Debt Total1.1 BB418 M
Slightly volatile
Deferred Long Term Liabilities11.9 M16.9 M11.9 M
Slightly volatile
Non Current Liabilities Other22.2 M23.3 M38.4 M
Slightly volatile
Capital Surpluse1.2 B2.3 B1.2 B
Slightly volatile
Short and Long Term Debt418.9 K441 K9.7 M
Slightly volatile
Net Invested Capital1.9 B1.8 B529.9 M
Slightly volatile
Net Working Capital467.4 M744.1 M293.5 M
Slightly volatile
Capital Stock222 K308.2 K183.8 K
Slightly volatile
Capital Lease Obligations37.9 M37.1 M45.2 M
Pretty Stable

Pacific Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization32 M30.5 M11.5 M
Slightly volatile
Total Revenue79 M154 M85.5 M
Slightly volatile
Gross Profit28.8 M37.3 M31.1 M
Slightly volatile
Other Operating Expenses535.9 M510.4 M242.9 M
Slightly volatile
Research Development89.8 M134.9 M83.4 M
Slightly volatile
Total Operating Expenses413.3 M393.7 M183.9 M
Slightly volatile
Cost Of Revenue70.2 M116.7 M58.4 M
Slightly volatile
Selling General Administrative203.9 M194.1 M88.6 M
Slightly volatile
Interest Income2.3 M2.3 M2.7 M
Slightly volatile
Reconciled Depreciation13.1 M22.3 M11.1 M
Slightly volatile
Non Recurring24.9 M28 M30.5 M
Slightly volatile

Pacific Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation87.1 M82.9 M34.7 M
Slightly volatile
Begin Period Cash Flow396.4 M377.6 M133.8 M
Slightly volatile
Depreciation32 M30.5 M11.5 M
Slightly volatile
Capital Expenditures5.9 M10.2 M5.7 M
Slightly volatile
End Period Cash Flow108.4 M206.9 M104.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.13.261525.0199
Slightly volatile
Capex To Depreciation0.360.380.7325
Slightly volatile
Inventory Turnover2.222.352.6252
Pretty Stable
Payables Turnover6.348.837.6559
Pretty Stable
Sales General And Administrative To Revenue0.880.931.9681
Slightly volatile
Research And Ddevelopement To Revenue0.830.8761.5459
Slightly volatile
Income Quality0.90.970.8282
Very volatile
Intangibles To Total Assets0.380.470.4218
Slightly volatile
Current Ratio9.658.988.3591
Very volatile
Receivables Turnover9.416.38.4611
Slightly volatile
Revenue Per Share0.50.56110.6443
Very volatile
Debt To Assets0.510.480.2343
Slightly volatile
Days Sales Outstanding40.359.9850.3442
Slightly volatile
Stock Based Compensation To Revenue0.390.410.3558
Very volatile
Days Of Inventory On Hand159161154
Slightly volatile
Capex To Revenue0.04820.05070.1519
Slightly volatile
Cash Per Share2.722.8610.6255
Slightly volatile
Days Payables Outstanding55.342.7952.1698
Slightly volatile
Capex Per Share0.03810.04010.0523
Slightly volatile
Interest Debt Per Share3.533.361.4644
Slightly volatile
Graham Number2.182.452.6728
Slightly volatile
Long Term Debt To Capitalization0.530.50.3174
Slightly volatile
Quick Ratio9.18.297.8017
Pretty Stable
Net Income Per E B T0.721.0010.8874
Slightly volatile
Cash Ratio2.072.183.7554
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.181.191.0767
Very volatile
Fixed Asset Turnover2.352.613.2417
Pretty Stable
Debt Ratio0.510.480.2343
Slightly volatile
Price Sales Ratio3.13.261525.0199
Slightly volatile
Asset Turnover0.09820.10.2993
Pretty Stable
Gross Profit Margin0.280.24210.349
Very volatile
Operating Cycle148186182
Pretty Stable
Days Of Payables Outstanding55.342.7952.1698
Slightly volatile
Cash Conversion Cycle110153137
Pretty Stable
Days Of Inventory Outstanding159161154
Slightly volatile
Days Of Sales Outstanding40.359.9850.3442
Slightly volatile

Pacific Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.5 B1.7 B3.5 B
Slightly volatile

Pacific Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pacific Biosciences Financial Statements

Pacific Biosciences stakeholders use historical fundamental indicators, such as Pacific Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Pacific Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pacific Biosciences' assets and liabilities are reflected in the revenues and expenses on Pacific Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pacific Biosciences of. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue18.8 M13.1 M
Total Revenue154 M79 M
Cost Of Revenue116.7 M70.2 M
Sales General And Administrative To Revenue 0.93  0.88 
Research And Ddevelopement To Revenue 0.88  0.83 
Revenue Per Share 0.56  0.50 
Stock Based Compensation To Revenue 0.41  0.39 
Capex To Revenue 0.05  0.05 
Ebit Per Revenue(2.31)(2.43)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:
Check out the analysis of Pacific Biosciences Correlation against competitors.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.58)
Revenue Per Share
0.561
Quarterly Revenue Growth
(0.33)
Return On Assets
(0.12)
Return On Equity
(0.51)
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.